Read More

Monte Rosa Therapeutics Presents Preclinical Data At ACR Convergence 2023 Demonstrating Potential Of MRT-6160, A VAV1-Targeted Molecular Glue Degrader, To Treat Immunological And Inflammatory Diseases

Data presented support broad potential therapeutic applications of MRT-6160 in a variety of autoimmune and inflammatory disorders driven by underlying dysregulation of T- and B-cells, including rheumatoid

GLUE